C4 Therapeutics, Inc. (CCCC) Shareholders’ equity 2021–2025
C4 Therapeutics, Inc. (CCCC) shareholders’ equity at each fiscal year-end, per SEC filings.
$256.6MFY2025 · since FY2021: $389.6M → $256.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $256.6M | +18.8% |
| FY2024 | $216.0M | -12.2% |
| FY2023 | $246.1M | -14.9% |
| FY2022 | $289.2M | -25.8% |
| FY2021 | $389.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice